Does AstraZeneca CEO Pascal Soriot really want to merge with Gilead? A Bloomberg story suggests he was interested — but it's hard to see why
Pascal Soriot has evidently been thinking big.
Completely out of left field, Bloomberg today posted a story early Sunday saying that AstraZeneca execs have approached Gilead to see if the big biotech would be interested in joining up in a historic biopharma merger. No numbers have been mentioned yet, and no decisions have been made. Right now, according to the business news service, it’s time to check everyone’s temperature.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.